(2)
Be The Match BioTherapies will provide streamlined supply chain services in support of Orchard s commercial-stage gene therapy in Europe Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to include supply chain services in support of the upcoming commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene), Orchard s gene therapy recently approved in Europe for the treatment of early-onset metachromatic leukodystrophy (MLD).
Through the expanded partnership, Be The Match BioTherapies will provide comprehensive support across the commercial supply chain for Libmeldy, including support of the onboarding and training of apheresis centers, oversight of the autologous cell collection process and delivery of both harvested cells to the manufacturin
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 Orchard Therapeutics (Europe) Limited London, UNITED KINGDOM
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic plann
Published: Jan 29, 2021
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business. Most recently, Mr. Parker served as Orchard’s senior vice president and general manager for North America.